Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229287 | 0.94 | HTR2A (0.46) | HTR2AHTR2CHTR2BCYP2A6PNMT | |
| SCHEMBL28292686 | 0.87 | HTR2A (0.57) | HTR2AHTR2CHTR2BCYP2A6GABRA1 | |
| SCHEMBL3677922 | 0.79 | HTR2A (0.71) | HTR2AHTR2CHTR2BCYP2A6GABRA1 | |
| SCHEMBL764989 | 0.78 | SLC6A2 (0.67) | HTR2ASLC6A2SLC6A3ALOX5AP | |
| SCHEMBL24819489 | 0.78 | HTR2A (0.48) | HTR2AHTR2CHTR2BCYP2A6GABRA1 | |
| SCHEMBL11405537 | 0.78 | HTR2A (0.63) | HTR2AHTR2CHTR2BCYP2A6GABRA1 | |
| SCHEMBL6566399 | 0.78 | CYP2A6 (0.54) | HTR2AHTR2CHTR2BCYP2A6GABRA1 | |
| SCHEMBL14018676 | 0.77 | CYP2A6 (0.61) | CYP2A6 | |
| SCHEMBL22095510 | 0.76 | HTR2A (0.47) | HTR2AHTR2CHTR2BGABRA1GABRB2 | |
| SCHEMBL2049886 | 0.76 | GABRA1 (0.53) | HTR2AHTR2CHTR2BGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-09 | — | — | US | disclosed |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2019028362-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | DYAX CORP. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168083-B2 | Inhibitors of Plasma Kallikrein and uses thereof | KLKB1, KLK1, KLK5 | HTR2A 3065/4885HTR2C 3437/4885HTR2B 2110/4885 |
| US-20200239463-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | HTR2A 3065/4885HTR2C 3437/4885HTR2B 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.